🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06059378
Active, not recruiting Not applicable

Using AI-assisted Optical Polyp Diagnosis for Diminutive Colorectal Polyps

NCT06059378 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2023-09-01
Last updated
2026-09-21

Condition(s) studied

Artificial Intelligence

Investigational drug(s) / intervention(s)

Artificial intelligence-assisted classification (CADx)

Artificial intelligence-assisted classification (CADx): CADeye (Fujifilm, Japan) is a joint detection (CADe) and classification (CADx) AI-supported system, which has been developed utilising AI deep learning technology to support endoscopic lesion detection and characterisation in the colon.

Study summary

This is a prospective study that is the first to implement resect and discard and diagnose and leave strategies in real-time practice using stringent documentation and adjudication by 2 expert endoscopists as the gold standard.

The primary aim of this study is to show the accuracy of intracolonoscopy AI-assisted optical diagnosis (CADx; autonomous or with human input) when the AI-assisted optical diagnosis made by the expert endoscopists is used as the reference standard. The specific aims are:

1. To evaluate the accuracy of intracolonoscopy AI-assisted optical polyp diagnosis (autonomous or with human input) by comparing it to the obtained optical histology diagnoses provided by two independent expert endoscopists as the reference standard.
2. To evaluate the agreement between the intracolonoscopy AI-assisted optical polyp diagnosis (autonomous or with human input) and the AI-assisted optical diagnosis performed by two independent expert endoscopists.
3. To determine whether AI-assisted optical polyp diagnosis for diminutive (1-5 mm) polyps can be implemented in routine clinical practice by demonstrating that at least 70% of the approached patients are interested in undergoing AI-assisted optical diagnosis (autonomous or with human input).
4. To evaluate the cost savings resulting from replacing pathology with AI-assisted optical diagnosis.

Eligibility

Sex
ALL
Min age
45 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age 45-80 years * Undergoing an outpatient colonoscopy at the Centre Hospitalier de l'Université de Montréal (CHUM) * Signed informed consent form Exclusion Criteria: * Inflammatory Bowel Disease; * Active colitis; * Hereditary CRC syndrome; * Coagulopathy; * American Society of Anesthesiologists (ASA) status \>3

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier de l'Université de Montréal Montreal Quebec

More Centre hospitalier de l'Université de Montréal (CHUM) trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06059378 on ClinicalTrials.gov ↗ ← All trials in Canada